Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Elu...(extensive randomized controlled clinical...)

Date:10/10/2008

extensive randomized, controlled clinical trial program, with follow-up to five years in some cases. These trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 4.6 million TAXUS stents have been implanted globally, making them the world's most frequently used drug-eluting stents.

The TAXUS Express2 stent (not the newer TAXUS Liberte stent) was used as the control against the Xience(TM) V Everolimus-Eluting Coronary Stent System in the SPIRIT II and III trials. XIENCE is a trademark of the Abbott Laboratories group of companies.

The TAXUS Liberte Stent is not available for sale in Japan, where it is undergoing regulatory review.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.
'/>"/>

SOURCE Boston Scientific Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. Video: Women Unsatisfied With Body and Breasts, Less Likely to Comply With Screenings, Including Mammography
2. Video: Moms Raise Red Flag About the Dangers of Widely Undiagnosed Bleeding Disorder
3. Video: Fortune 1000 Executives: New President Must Fix Education Gap
4. Video: Keppra XR(TM) Approved in the U.S.
5. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
6. Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
7. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
8. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
9. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
10. Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality:
11. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges